| 1.62 -0.08 (-4.71%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.14  |
1-year : | 2.31 |
| Resists | First : | 1.83 |
Second : | 1.98 |
| Pivot price | 1.78 |
|||
| Supports | First : | 1.6 |
Second : | 1.33 |
| MAs | MA(5) : | 1.72 |
MA(20) : | 1.8 |
| MA(100) : | 3.38 |
MA(250) : | 8.37 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2  |
| %K %D | K(14,3) : | 5.3 |
D(3) : | 10.7 |
| RSI | RSI(14): 30.3 |
|||
| 52-week | High : | 29.7 | Low : | 1.37 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ APVO ] has closed below the lower bollinger band by 9.6%. Bollinger Bands are 70% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.69 - 1.7 | 1.7 - 1.71 |
| Low: | 1.58 - 1.59 | 1.59 - 1.6 |
| Close: | 1.6 - 1.62 | 1.62 - 1.64 |
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
Wed, 14 Oct 2026
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting - FinancialContent
Wed, 14 Oct 2026
Two immune defenses are central to an approach Aptevo will present at a cancer meeting. - Stock Titan
Sat, 10 Oct 2026
Aptevo Therapeutics (APVO) Slips to $1.79 as Shares Test Lower End of Recent Range - Chart Pattern Alerts - dars.gov.et
Fri, 14 Aug 2026
Aptevo APVO Reports Q2 2026 Update With $9.8 Million Cash - Quiver Quantitative
Wed, 12 Aug 2026
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 4.1 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 119 (K) |
| Shares Short P.Month | 118 (K) |
| EPS | 66.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -111.5 % |
| Return on Equity (ttm) | -420.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -14.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | 0.02 |
| PEG Ratio | 0 |
| Price to Book value | 0.38 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|